Type I Interferon-mediated Monogenic Autoinflammation: The Type I Interferonopathies, a Conceptual Overview

Overview

Journal J Exp Med

Specialties Allergy & Immunology
General Medicine

Date 2016 Nov 9

PMID 27821552

Citations 211

Authors

Mathieu P Rodero

Yanick J Crow

Affiliations

Soon will be listed here.

Abstract

Type I interferon is a potent substance. As such, the induction, transmission, and resolution of the type I interferon-mediated immune response are tightly regulated. As defined, the type I interferonopathies represent discrete examples of a disturbance of the homeostatic control of this system caused by Mendelian mutations. Considering the complexity of the interferon response, the identification of further monogenic diseases belonging to this disease grouping seems likely, with the recognition of type I interferonopathies becoming of increasing clinical importance as treatment options are developed based on an understanding of disease pathology and innate immune signaling. Definition of the type I interferonopathies indicates that autoinflammation can be both interferon and noninterferon related, and that a primary disturbance of the innate immune system can "spill over" into autoimmunity in some cases. Indeed, that several non-Mendelian disorders, most particularly systemic lupus erythematosus and dermatomyositis, are also characterized by an up-regulation of type I interferon signaling suggests the possibility that insights derived from this work will have relevance to a broader field of clinical medicine.

Citing Articles

NF-κB RelB suppresses the inflammatory gene expression programs of dendritic cells by competing with RelA for binding to target gene promoters.

Navarro H, Daly A, Rodriguez B, Wu S, Ngo K, Fraser A Cell Discov. 2025; 11(1):13.

PMID: 39929805 PMC: 11811218. DOI: 10.1038/s41421-024-00767-9.

Clinical, laboratory, and molecular characteristics of patients with spondyloenchondrodysplasia: a case series study.

Sahinoglu E, Oren A, Sahinoglu B, Keskin O, Damar C, Akbayram S Eur J Pediatr. 2025; 184(2):152.

PMID: 39853520 DOI: 10.1007/s00431-025-05982-4.

A Wonderful Journey: The Diverse Roles of Adenosine Deaminase Action on RNA 1 (ADAR1) in Central Nervous System Diseases.

Cheng L, Liu Z, Shen C, Xiong Y, Shin S, Hwang Y CNS Neurosci Ther. 2025; 31(1):e70208.

PMID: 39753993 PMC: 11702419. DOI: 10.1111/cns.70208.

JAK inhibition decreases the autoimmune burden in Down syndrome.

Rachubinski A, Wallace E, Gurnee E, Enriquez-Estrada B, Worek K, Smith K Elife. 2024; 13.

PMID: 39737640 PMC: 11687933. DOI: 10.7554/eLife.99323.

Overexpression of Egr1 Transcription Regulator Contributes to Schwann Cell Differentiation Defects in Neural Crest-Specific Knockout Mice.

Zerad L, Gacem N, Gayda F, Day L, Sinigaglia K, Richard L Cells. 2024; 13(23).

PMID: 39682701 PMC: 11639873. DOI: 10.3390/cells13231952.

References

Kauffman W, Sivit C, Fitz C, Rakusan T, Herzog K, Chandra R . CT and MR evaluation of intracranial involvement in pediatric HIV infection: a clinical-imaging correlation. AJNR Am J Neuroradiol. 1992; 13(3):949-57. PMC: 8331707. View

Aicardi J, Goutieres F . A progressive familial encephalopathy in infancy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis. Ann Neurol. 1984; 15(1):49-54. DOI: 10.1002/ana.410150109. View

Akwa Y, Hassett D, Eloranta M, Sandberg K, Masliah E, Powell H . Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J Immunol. 1998; 161(9):5016-26. View

Wang B, Higgs B, Chang L, Vainshtein I, Liu Z, Streicher K . Pharmacogenomics and translational simulations to bridge indications for an anti-interferon-α receptor antibody. Clin Pharmacol Ther. 2013; 93(6):483-92. DOI: 10.1038/clpt.2013.35. View

Al-Zahrani H, Gupta V, Minden M, Messner H, Lipton J . Vascular events associated with alpha interferon therapy. Leuk Lymphoma. 2003; 44(3):471-5. DOI: 10.1080/1042819021000055066. View

Konig N, Fiehn C, Wolf C, Schuster M, Cura Costa E, Tungler V . Familial chilblain lupus due to a gain-of-function mutation in STING. Ann Rheum Dis. 2016; 76(2):468-472. DOI: 10.1136/annrheumdis-2016-209841. View

Gao D, Li T, Li X, Chen X, Li Q, Wight-Carter M . Activation of cyclic GMP-AMP synthase by self-DNA causes autoimmune diseases. Proc Natl Acad Sci U S A. 2015; 112(42):E5699-705. PMC: 4620884. DOI: 10.1073/pnas.1516465112. View

Santer D, Hall B, George T, Tangsombatvisit S, Liu C, Arkwright P . C1q deficiency leads to the defective suppression of IFN-alpha in response to nucleoprotein containing immune complexes. J Immunol. 2010; 185(8):4738-49. PMC: 3065655. DOI: 10.4049/jimmunol.1001731. View

An J, Briggs T, Dumax-Vorzet A, Alarcon-Riquelme M, Belot A, Beresford M . Tartrate-Resistant Acid Phosphatase Deficiency in the Predisposition to Systemic Lupus Erythematosus. Arthritis Rheumatol. 2016; 69(1):131-142. DOI: 10.1002/art.39810. View

10.

Jeremiah N, Neven B, Gentili M, Callebaut I, Maschalidi S, Stolzenberg M . Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. J Clin Invest. 2014; 124(12):5516-20. PMC: 4348945. DOI: 10.1172/JCI79100. View

11.

Sobolev O, Binda E, OFarrell S, Lorenc A, Pradines J, Huang Y . Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events. Nat Immunol. 2016; 17(2):204-13. PMC: 6485475. DOI: 10.1038/ni.3328. View

12.

Bursztejn A, Briggs T, del Toro Duany Y, Anderson B, OSullivan J, Williams S . Unusual cutaneous features associated with a heterozygous gain-of-function mutation in IFIH1: overlap between Aicardi-Goutières and Singleton-Merten syndromes. Br J Dermatol. 2015; 173(6):1505-13. PMC: 4745891. DOI: 10.1111/bjd.14073. View

13.

Rice G, Kasher P, Forte G, Mannion N, Greenwood S, Szynkiewicz M . Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature. Nat Genet. 2012; 44(11):1243-8. PMC: 4154508. DOI: 10.1038/ng.2414. View

14.

Baechler E, Batliwalla F, Karypis G, Gaffney P, Ortmann W, Espe K . Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003; 100(5):2610-5. PMC: 151388. DOI: 10.1073/pnas.0337679100. View

15.

Isaacs A, Lindenmann J, Valentine R . Pillars Article: Virus Interference. II. Some Properties of Interferon. Proc R Soc Lond B Biol Sci. 1957. 147: 268-273. J Immunol. 2015; 195(5):1921-6. View

16.

Belot A, Wassmer E, Twilt M, Lega J, Zeef L, Oojageer A . Mutations in CECR1 associated with a neutrophil signature in peripheral blood. Pediatr Rheumatol Online J. 2014; 12:44. PMC: 4181355. DOI: 10.1186/1546-0096-12-44. View

17.

Kavanagh D, McGlasson S, Jury A, Williams J, Scolding N, Bellamy C . Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature. Blood. 2016; 128(24):2824-2833. PMC: 5159705. DOI: 10.1182/blood-2016-05-715987. View

18.

Ducreux J, Houssiau F, Vandepapeliere P, Jorgensen C, Lazaro E, Spertini F . Interferon α kinoid induces neutralizing anti-interferon α antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts: analysis of extended follow-up data from the interferon α kinoid phase I/II.... Rheumatology (Oxford). 2016; 55(10):1901-5. PMC: 5034220. DOI: 10.1093/rheumatology/kew262. View

19.

Gall A, Treuting P, Elkon K, Loo Y, Gale Jr M, Barber G . Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease. Immunity. 2012; 36(1):120-31. PMC: 3269499. DOI: 10.1016/j.immuni.2011.11.018. View

20.

Crow Y, Zaki M, Abdel-Hamid M, Abdel-Salam G, Boespflug-Tanguy O, Cordeiro N . Mutations in ADAR1, IFIH1, and RNASEH2B presenting as spastic paraplegia. Neuropediatrics. 2014; 45(6):386-93. DOI: 10.1055/s-0034-1389161. View